Natalia Jedruchniewicz
Overview
Explore the profile of Natalia Jedruchniewicz including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
13
Citations
126
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Wierzbicka M, Kiszka M, Barnas S, Jeziorny M, Zajac B, Dwornikowska-Dabrowska M, et al.
Otolaryngol Pol
. 2025 Mar;
79(3):1-7.
PMID: 40084835
<b>Introduction:</b> The Ready for Safe Cancer Treatment (RESET) tool is a structured, multimodal program designed to optimize hospitalization and enhance the quality of perioperative care for oncological patients. While RESET...
2.
Buzalewicz I, Kaczorowska A, Fijalkowski W, Pietrowska A, Matczuk A, Podbielska H, et al.
Int J Mol Sci
. 2024 Mar;
25(5).
PMID: 38473902
The increase in bacterial resistance to antibiotics in recent years demands innovative strategies for the detection and combating of biofilms, which are notoriously resilient. Biofilms, particularly those on contact lenses,...
3.
Harhala M, Gembara K, Baniecki K, Pikies A, Nahorecki A, Jedruchniewicz N, et al.
Viruses
. 2024 Jan;
16(1).
PMID: 38257758
Multiple pathogens are competing against the human immune response, leading to outbreaks that are increasingly difficult to control. For example, the SARS-CoV-2 virus continually evolves, giving rise to new variants....
4.
Szewczyk-Dabrowska A, Budziar W, Harhala M, Baniecki K, Pikies A, Jedruchniewicz N, et al.
Sci Rep
. 2022 Sep;
12(1):15944.
PMID: 36153350
Predictors for the risk of severe COVID-19 are crucial for patient care and control of the disease. Other infectious diseases as potential comorbidities in SARS-CoV-2 infection are still poorly understood....
5.
Szewczyk-Dabrowska A, Budziar W, Baniecki K, Pikies A, Harhala M, Jedruchniewicz N, et al.
PLoS One
. 2022 Sep;
17(9):e0274095.
PMID: 36083875
The immune response and specific antibody production in COVID-19 are among the key factors that determine both prognostics for individual patients and the global perspective for controlling the pandemics. So...
6.
Dalek P, Drabik D, Wolczanska H, Forys A, Jagas M, Jedruchniewicz N, et al.
Nanomedicine
. 2022 Mar;
43:102552.
PMID: 35346834
Vitamin D3 deficiency has serious health consequences, as demonstrated by its effect on severity and recovery after COVID-19 infection. Because of high hydrophobicity, its absorption and subsequent redistribution throughout the...
7.
Budziar W, Gembara K, Harhala M, Szymczak A, Jedruchniewicz N, Baniecki K, et al.
PLoS One
. 2022 Feb;
17(2):e0253638.
PMID: 35113873
Population immunity (herd immunity) to SARS-CoV-2 derives from two sources: vaccinations or cases of infection with the virus. Infections can be diagnosed as COVID-19 and registered, or they can be...
8.
Dubis J, Niepieklo-Miniewska W, Jedruchniewicz N, Sobczynski M, Witkiewicz W, Zapotoczny N, et al.
Cells
. 2021 Dec;
10(12).
PMID: 34943866
Abdominal aortic aneurysm (AAA) is an immune-mediated disease with a genetic component. The multifactorial pathophysiology is not clear and there is still no pharmacotherapy to slow the growth of aneurysms....
9.
Szymczak A, Jedruchniewicz N, Torelli A, Kaczmarzyk-Radka A, Coluccio R, Klak M, et al.
J Gen Virol
. 2021 Nov;
102(11).
PMID: 34816794
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has spread globally; recognition of immune responses to this virus will be crucial for coronavirus disease 2019 (COVID-19) control, prevention and treatment. We...
10.
Wisniewski A, Sobczynski M, Pawelczyk K, Porebska I, Jasek M, Wagner M, et al.
Front Immunol
. 2021 Jun;
12:664474.
PMID: 34149699
Lung cancer is strongly associated with cigarette smoking; nevertheless some never-smokers develop cancer. Immune eradication of cancer cells is dependent on polymorphisms of HLA class I molecules and antigen-processing machinery...